Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.125 1.66% 7.65 7.50 7.80 7.65 7.525 7.53 294,871 15:03:31
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.8 -0.5 -0.2 - 16

Eden Research Share Discussion Threads

Showing 7376 to 7397 of 8375 messages
Chat Pages: Latest  299  298  297  296  295  294  293  292  291  290  289  288  Older
DateSubjectAuthorDiscuss
26/6/2019
07:30
It would be good if Eden could give a simple break down of sales to revenue, with costs to earnings.Yep I agree but there is not a lot of chance that will happen.. I have been asking this for years but the management deem it not for our consumption even to save their share options, I doubt it will happen...Tick tick jam tomorrow Shareholders are an inconvenience to the grand plan in the short order of things..
bjlk
25/6/2019
17:29
Eden Research @edenresearch Eden Research plc Retweeted The Biopesticide Summit 2019 Felicity Lenyk will be presenting on Eden's #Sustaine encapsulation technology at the @biosummit19 on the 2-3rd July in Swansea. Felicity Lenyk from @edenresearch and Majda Ortan from #PHAgrohom adding to our line up, both very inspiring women! hTTps://twitter.com/biosummit19/status/1143543999980023808 hTTps://biopesticidesummit.com/biopesticide-summit-uk-2019-home/biopesticide-summit-2019-speakers/
supersonico
25/6/2019
17:09
BBC Radio 4 today Among others, plastic and shampoo https://www.bbc.co.uk/programmes/m000674n
investingisatrickygame
25/6/2019
14:55
hTTps://www.youtube.com/watch?v=JZYWYK4GbAo&list=PLP4P7rl8GkSdcrwFOsvO4shVVxlERLXK0&index=5&t=0s Grateful to Super for putting me onto this guy. This video of a lecture in Germany is of material interest to what EDEN provide, including, 16 minutes in, a mention of the risk posed by canine flea treatments. 3/4 of the world's bees have neonicotinoids in their foods.
brucie5
25/6/2019
14:40
I wonder if EDEN should give these guys a call. hTTps://www.bluemaia.com/
brucie5
25/6/2019
12:39
"If a capital injection would drive this through more quickly through investment in people and more when is this likely to happen, by what mechanism and if share price related, at what price point?" I think that is what Wan, among others, are expecting. The natural opportunity would be when those partnering Sipcam in their evaluation of the tech finally declare their hands. I expect there to be some kind of concomitant 'Open Offer', as in 2017, so all can take whatever further stake they wish. There will be dilution, but also any amount of cash needed to do as you suggest. Re. the executive options, I don't think we can expect too much here. If they suddenly whisk something out the hat just in time to cash in, they might be accused of opportunism and worse. If the share price doubles, it will be because EDEN is able to show something more exciting and immediate that it has managed thus far. As to your underlying concerns about patent life, yes, I share your concerns somewhat. Though I did read somewhere that there are circumstances to do with product use where the patents can be extended. Might be on the Shore Report.
brucie5
25/6/2019
09:48
From Page 7 of the 2018 Annual Report and Accounts Furthermore, we have filed applications for Supplementary Protection Certificates (‘SPCs’) covering Mevalone in key countries. SPCs effectively extend the patent protection of products that require regulatory approval before they can be sold in a given jurisdiction. They provide up to an additional seven years of patent protection, depending upon the territory. In total, SPCs have now been awarded in Spain, Greece, Italy and Cyprus, and there are pending applications in France and Portugal. There are now a total of 130 (2016: 112) granted or pending patents in Eden’s ‘owned’ portfolio, not including patents under licence from the University of Massachusetts From page 9 of the 2018 Annual Report and Accounts Intellectual property, including development expenditure, is written off over seven years in line with the remaining life of the Company’s key patents. From page 25 of the 2018 Annual Report and Accounts Intangible assets Intellectual property, including development costs, is capitalised and amortised on a straight-line basis over its remaining estimated useful economic life of 7 years in line with the remaining life of the Company’s master patent, which was originally 20 years. The useful economic life of intangible assets is reviewed on an annual basis. Allowing for the SPC's when does the Mevalone patent expire? When do the other patents granted expire? I ask this because this all goes to the underlying value of the business, does it not? And the re-granting of patents is not automatic so however good we may think Eden's products are now, there is no standing still because who knows what developments and technologies may rear their head to compete with or exceed what Eden has or is about to achieve. So with this is mind and the regulatory timeframe and in-house then field trials, marketing, commercial launch etc, is Eden (like any other similar player) up against the clock to establish market share and revenue? If so, how can they best escalate that? If a capital injection would drive this through more quickly through investment in people and more when is this likely to happen, by what mechanism and if share price related, at what price point? There are 1,908,608 shares granted on the 29/9/2017 vesting for 2 years. There are also 3,350,000 warrants in play with no vesting period, but a weighted average contractual life of 1.9 years, so I assume some of these are coming into play. This information is taken from page 43 of the 2018 Annual Report and Accounts. I can only see weighted average price 'ranges' and not a single average weighted price so I am unsure as to the specific price point, if there is one in relation to 29/9/2017 shares. So the share price is extremely important in driving business growth and also for executives to benefit over and above salaries and bonuses which AGAIN means to me that this ridiculous 10-11p share price can not stay as it is for very much longer because the clock really is ticking.
investingisatrickygame
25/6/2019
09:08
For those who follow the Dots of Sumitomo related companies ..this post by Vittoria Percivalle of Sumitomo makes intriguing Reading Cucurbitacce: solutions for the defence of OIDIO In addition to the products mentioned in the article of the Agricultural Informant, in addition to Orange Oil (PREV-AM PLUS) I point out that Cerevisane (ROMEO) is also allowed! #thinkbiorational #biorational Sumitomo Chemical Italia Claudio Lama Agrauxine by Lesaffre hTTps://www.linkedin.com/feed/update/urn:li:activity:6549002367457730560
supersonico
25/6/2019
07:42
hxxp://www.edenresearch.com/~/media/Files/E/Eden-Research/documents/reports-and-presentation/agm-presentation-2016.pdf Then go to pages 10 & 11
wilmer100
24/6/2019
19:41
Also I'm thinking 5 years out from now. I'd be happy to with Half that share price but I would like more. £1-2 with a 5% dividend yield would be very nice.
wilmer100
24/6/2019
19:22
Your right, future addressable markets $4B, but with a 5% penetration = $200000000. 12.5% margin, which I think is generous considering they are using toll manufactures and they need a profit.= $25000000 with a PE of 20. = $500000000 X 0.8 to account for the exchange rate and you have £4000000000 Roughly £2/share. Very crude I know. Its the %5 penetration I think is conservative, I think it could be a lot more.
wilmer100
24/6/2019
18:06
Thanks What % market penetration are you assuming... And what PE once it hits earnings? 12% margin seems very lowly. The 4bln total addressable I believe includes everything aside from Sustaine. But I would be very happy with half that share price over three years.
brucie5
24/6/2019
17:31
I've been following this company since it was on the PLUS market and started investing in it a little after it listed on the AIM market. Originally I was looking for a royalty income company which this was working towards being but has now change I think for the better. When I first started investing in this I was thinking that if they could get a 10% share of a total crop protection market of $45B with royalties of between 3 and 5% this would be a very successful company. The company is now about sales. My guesstimate is that they would receive 12.5% profit on sales. They are working towards combined markets totalling 4$B in crop protection. If they could achieve 5% market share this, by my reckoning would value the company at about £2/share, and that's not including animal and consumer products. I can wait a little longer for a 20+ fold return on my investment.
wilmer100
24/6/2019
14:50
Mevalone Trade Names. Two I knew... Three I did not. Label extensions Perhaps? NIRKA, YATTO TRIGEMOL EUGETI CAGENOLETA hTTps://ephy.anses.fr/ppp/mevalone hTTps://www.ecophytopic.fr/sites/default/files/actualites_doc/2019-462_final.pdf
supersonico
24/6/2019
12:57
Replicated post.
brucie5
24/6/2019
12:57
Ok. I'd be interested to know why you have been such a long term supporter, given the timeline to profits. And to what extent you believe your original hopes, aside from timeframe, are being vindicated.
brucie5
24/6/2019
12:57
Ok. I'd be interested to know why you have been such a long term supporter, given the timeline to profits. And to what extent you believe your original hopes, aside from timeframe, are being vindicated.
brucie5
24/6/2019
12:57
Ok. I'd be interested to know why you have been such a long term supporter, given the timeline to profits. And to what extent you believe your original hopes, aside from timeframe, are being vindicated.
brucie5
24/6/2019
12:57
Ok. I'd be interested to know why you have been such a long term supporter, given the timeline to profits. And to what extent you believe your original hopes, aside from timeframe, are being vindicated.
brucie5
24/6/2019
12:56
Ok. I'd be interested to know why you have been such a long term supporter, given the timeline to profits. And to what extent you believe your original hopes, aside from timeframe, are being vindicated.
brucie5
24/6/2019
12:56
Ok. I'd be interested to know why you have been such a long term supporter, given the timeline to profits. And to what extent you believe your original hopes, aside from timeframe, are being vindicated.
brucie5
24/6/2019
12:56
Ok. I'd be interested to know why you have been such a long term supporter, given the timeline to profits. And to what extent you believe your original hopes, aside from timeframe, are being vindicated.
brucie5
Chat Pages: Latest  299  298  297  296  295  294  293  292  291  290  289  288  Older
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191213 15:55:21